{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T21:11:22Z","timestamp":1772485882882,"version":"3.50.1"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"38","license":[{"start":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T00:00:00Z","timestamp":1632441600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"crossref","award":["109255"],"award-info":[{"award-number":["109255"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) remains a major therapeutic challenge. In recent years, new molecular-targeted therapies, such as cabozantinib, have been approved for the treatment of advanced HCC. However, clinical experience with these new drugs in the treatment of HCC in the LT setting is very limited.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>In 2003, a 36-year-old woman was referred to the hospital with right upper abdominal pain.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>An initial ultrasound of the liver demonstrated a large unclear lesion of the left lobe of the liver. The magnet resonance imaging findings confirmed a multifocal inoperable HCC in a non-cirrhotic liver. Seven years after receiving a living donor LT, pulmonary and intra-hepatic recurrence of the HCC was radiologically diagnosed and histologically confirmed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Following an interdisciplinary therapy concept consisting of surgical, interventional-radiological (with radiofrequency ablation [RFA]) as well as systemic treatment, the patient achieved a survival of more than 10 years after tumor recurrence. As systemic first line therapy with sorafenib was accompanied by grade 3 to 4 toxicities, such as mucositis, hand-foot skin reaction, diarrhea, liver dysfunction, and hyperthyroidism, it had to be discontinued. After switching to cabozantinib from June 2018 to April 2020, partial remission of all tumor manifestations was achieved. The treatment of the remaining liver metastasis could be completed by RFA. The therapy with cabozantinib was well tolerated, only mild arterial hypertension and grade 1 to 2 mucositis were observed. Liver transplant function was stable during the therapy, no drug interaction with immunosuppressive drugs was observed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>More than 10 years survival after recurrence of HCC after living-donor LT due to intensive multimodal therapy concepts, including surgery, RFA, and systemic therapy with cabozantinib in the second line therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>In conclusion, this report highlights the tolerability and effectiveness of cabozantinib for the treatment of HCC recurrence after LT. We show that our patient with a late recurrence of HCC after LT benefitted from intensive multimodal therapy concepts, including surgery, RFA, and systemic therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000027082","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T16:54:07Z","timestamp":1632502447000},"page":"e27082","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Multimodal and systemic therapy with cabozantinib for treatment of recurrent hepatocellular carcinoma after liver transplantation"],"prefix":"10.1097","volume":"100","author":[{"given":"Robert","family":"Mahn","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, University Hospital Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farsaneh","family":"Sadeghlar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Hospital Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Bartels","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Hospital Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taotao","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Hospital Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Weism\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Hospital Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Kupczyk","sequence":"additional","affiliation":[{"name":"Department of Radiology, University Hospital Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Meyer","sequence":"additional","affiliation":[{"name":"Department of Radiology, University Hospital Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian C.","family":"Gaertner","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marieta","family":"Toma","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Vilz","sequence":"additional","affiliation":[{"name":"Department of Visceral Surgery, University Hospital Bonn, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Knipper","sequence":"additional","affiliation":[{"name":"Department of Visceral Surgery, University Hospital Bonn, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Glowka","sequence":"additional","affiliation":[{"name":"Department of Visceral Surgery, University Hospital Bonn, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Manekeller","sequence":"additional","affiliation":[{"name":"Department of Visceral Surgery, University Hospital Bonn, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Kalff","sequence":"additional","affiliation":[{"name":"Department of Visceral Surgery, University Hospital Bonn, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian P.","family":"Strassburg","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Hospital Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3956-1457","authenticated-orcid":false,"given":"Maria A.","family":"Gonzalez-Carmona","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, University Hospital Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,9,24]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"03","DOI":"10.1016\/j.jviscsurg.2010.12.012","article-title":"Hepatocellular cancer in the non-cirrhotic liver","volume":"148","author":"Alkofer","year":"2011","journal-title":"J Visc Surg"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"W34","DOI":"10.2214\/AJR.13.11511","article-title":"Hepatocellular carcinoma in the noncirrhotic liver","volume":"203","author":"Gaddikeri","year":"2014","journal-title":"Am J Roentgenol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1056\/NEJMra065156","article-title":"Strategies for safer liver surgery and partial liver transplantation","volume":"356","author":"Clavien","year":"2007","journal-title":"N Engl J Med"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/bjs.4763","article-title":"Liver resection for hepatocellular carcinoma in non-cirrhotic liver without underlying viral hepatitis","volume":"92","author":"Lang","year":"2005","journal-title":"Br J Surg"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1053\/jhep.2001.23561","article-title":"Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis","volume":"33","author":"Jonas","year":"2001","journal-title":"Hepatology"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/liv.14346","article-title":"Liver transplantation as therapy for hepatocellular carcinoma","volume":"40","author":"Kim","year":"2020","journal-title":"Liver Int"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S1470-2045(11)70175-9","article-title":"Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report","volume":"13","author":"Clavien","year":"2012","journal-title":"Lancet Oncol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/ctr.12534","article-title":"Liver transplantation for hepatocellular carcinoma comparing the Milan, UCSF, and Asan criteria: long-term follow-up of a Western single institutional experience","volume":"29","author":"Bonadio","year":"2015","journal-title":"Clin Transplant"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jhep.2012.03.022","article-title":"Liver transplantation for unresectable hepatocellular carcinoma in normal livers","volume":"57","author":"Mergental","year":"2012","journal-title":"J Hepatol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.2217\/fon.15.239","article-title":"Recurrence of hepatocellular carcinoma after liver transplantation: an update","volume":"11","author":"Mazzola","year":"2015","journal-title":"Future Oncol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/ctr.12286","article-title":"The prognosis and treatment outcomes of patients with recurrent hepatocellular carcinoma after liver transplantation","volume":"28","author":"Roh","year":"2014","journal-title":"Clin Transplant"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"659","DOI":"10.12659\/AOT.910598","article-title":"Clinical features and surveillance of very late hepatocellular carcinoma recurrence after liver transplantation","volume":"23","author":"Alshahrani","year":"2018","journal-title":"Ann Transplant"},{"key":"R15-20250504","first-page":"3421","article-title":"Multimodal oncological approach in patients affected by recurrent hepatocellular carcinoma after liver transplantation","volume":"21","author":"Guerrini","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncology"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/lt.22434","article-title":"Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation","volume":"18","author":"Gomez-Martin","year":"2012","journal-title":"Liver Transpl"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jhep.2013.02.026","article-title":"Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study","volume":"59","author":"Sposito","year":"2013","journal-title":"J Hepatol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1111\/ajt.15551","article-title":"Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation","volume":"19","author":"Lavarone","year":"2019","journal-title":"Am J Transplant"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.dld.2009.09.002","article-title":"Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal","volume":"42","author":"Trevisani","year":"2010","journal-title":"Dig Liver Dis"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.4254\/wjh.v11.i1.1","article-title":"Hepatocellular carcinoma in non-cirrhotic liver: a comprehensive review","volume":"11","author":"Desai","year":"2019","journal-title":"World J Hepatol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1002\/lt.23490","article-title":"Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: a meta-analysis","volume":"18","author":"Liang","year":"2012","journal-title":"Liver Transpl"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/MOT.0000000000000692","article-title":"How far can we go with hepatocellular carcinoma in living donor liver transplantation?","volume":"24","author":"Limkemann","year":"2019","journal-title":"Curr Opin Organ Transplant"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1097\/MEG.0000000000001448","article-title":"Hepatocellular carcinoma recurrence after liver transplantation in a Brazilian multicenter study: clinical profile and prognostic factors of survival","volume":"31","author":"Chagas","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/SLA.0000000000001894","article-title":"Predicting mortality in patients developing recurrent hepatocellular carcinoma after liver transplantation: impact of treatment modality and recurrence characteristics","volume":"266","author":"Bodzin","year":"2017","journal-title":"Ann Surg"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/lt.24742","article-title":"Recurrence of hepatocellular carcinoma after liver transplantation: is there a place for resection?","volume":"23","author":"Fernandez-Sevilla","year":"2017","journal-title":"Liver Transpl"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/PL00009947","article-title":"Pattern and management of recurrent hepatocellular carcinoma after liver transplantation","volume":"5","author":"Regalia","year":"1998","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/lt.23911","article-title":"Sorafenib use in the transplant setting","volume":"20","author":"Castelli","year":"2014","journal-title":"Liver Transpl"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/lt.25191","article-title":"Antitumor effect of sorafenib and mammalian target of rapamycin inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence","volume":"24","author":"Jung","year":"2018","journal-title":"Liver Transpl"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/TP.0000000000002955","article-title":"Experience with early sorafenib treatment with mTOR inhibitors in hepatocellular carcinoma recurring after liver transplantation","volume":"104","author":"Invernizzi","year":"2020","journal-title":"Transplantation"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/j.1432-2277.2012.01540.x","article-title":"High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation","volume":"25","author":"Staufer","year":"2012","journal-title":"Transpl Int"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:12:49Z","timestamp":1746335569000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027082"}},"subtitle":["A case report with long term follow-up outcomes"],"short-title":[],"issued":{"date-parts":[[2021,9,24]]},"references-count":36,"journal-issue":{"issue":"38","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000027082","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,24]]},"assertion":[{"value":"2021-06-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}